Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ARQTthis companyArcutis Biotherapeutics, Inc.	$25.74	-223.38×	19.5×	9.82×	2,055.19×	-632.3%	90.2%	-3.3%	-4.3%	-8.5%	-4.0%	-0.2%	0.03×	-20.58×	-1.01×	3.17×	0.0%	7	7.53	2	C+
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ALDXAldeyra The	$0.66	-9.25×	7.03×	0×	-8.1×	55.2%	0.0%	0.0%	0.0%	-76.5%	-59.0%	-10.7%	0.35×	1.72×	-18.51×	2.58×	0.0%	2	-12.88	2	B-
EVMNEvommune, Inc.	$7.28	-1.53×	0.51×	8.08×	-0.79×	-2667.3%	100.0%	-623.6%	-529.8%	-33.5%	-39.1%	-73.0%	0.01×	0.53×	0×	8.57×	0.0%	4	4.4	2	C+
TTRXTurn Therapeutics Inc.	$9.84	-17.13×	11.55×	0×	-15.65×	-98.2%	0.0%	0.0%	0.0%	-68.2%	-94.4%	-5.0%	0.02×	1.59×	0×	0.87×	0.0%	1	7.69	1	D+
Peer median	—	-7.46×	5.31×	4.04×	-6.77×	-110.2%	36.6%	-311.8%	-264.9%	-65.6%	-58.3%	-11.7%	0.02×	1.06×	0×	3.93×	0.0%	2	0.87	2	—